Sartorius Stedim Biotech Confirms And Partially Refines Guidance For 2026

By Reuters News

Oct 22 (Reuters) - Sartorius Stedim Biotech STDM.PA:

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EBITDA EUR 716 MILLION

  • SARTORIUS STEDIM BIOTECH 9M CASH FLOW FROM OPERATING ACTIVITIES EUR 497.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED NET INCOME EUR 349.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M REVENUE EUR 2,289.2 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EPS EUR 3.59

  • SARTORIUS STEDIM BIOTECH 9M NET INCOME EUR 276.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M EPS EUR 2.84

  • MANAGEMENT CONFIRMS AND PARTIALLY REFINES GUIDANCE FOR 2026

  • CONFIRMS ITS SALES AND PROFITABILITY GUIDANCE FOR FY AND REFINES EXPECTED RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE

  • OUTLOOK 2026: RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE IS NOW EXPECTED TO BE AROUND 13 PERCENT

  • OUTLOOK 2026: RATIO OF NET DEBT TO UNDERLYING EBITDA SHOULD DECREASE TO SLIGHTLY ABOVE 2 (PY: 2.38)

Further company coverage: [STDM.PA]

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.